Rahul Barve, Radiation Oncologist at BC Cancer, Neuro-Oncology, Head and Neck Oncology, Brachytherapy Specialist, shared a post on LinkedIn:
“Brain Metastasis Velocity (BMV) is one of the most clinically relevant prognostic biomarkers in the management of brain metastases.
Rather than simply counting lesions, BMV measures the tempo of intracranial disease progression and has been shown to predict survival, neurologic outcomes, and the need for salvage WBRT.
This article explores how BMV may help guide treatment decisions today and how its integration with molecular profiling, CSF ctDNA, and systemic therapy response could shape the future of precision neuro-oncology.”
Other articles about Neuro-oncology on OncoDaily.